Non-IgG antibodies have been reported to be effective in the treatment of diverse tumors including colon carcinoma in vivo and in vitro. Over years of hard work, Creative Biolabs has established a professional team and advanced platforms to better provide non-IgG therapeutic antibodies service to global customers.
Background of Colon Carcinoma Treatment
Colorectal cancer (CRC) is the second leading cause of cancer mortality worldwide and the third most frequently diagnosed malignancy after lung and breast cancer. To date, in addition to the conventional drugs, antibody-based immunotherapy targeting tumor-associated antigens in cancer has recently emerged and been widely used in the clinic, which may serve as another effective tool for CRC therapy. Antibody therapy, particularly monoclonal antibodies (mAbs), induces anti-tumor activity not only by directly blocking the vital signal provided by the target molecule but also by stimulating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. mAbs are a particularly promising tool due to their target specificity and strong anti-tumor activity through a variety of mechanisms. Recently, non-IgG antibodies have been demonstrated with greater anti-tumor therapeutic potential than conventional IgGs in various cancer research.
IgA Antibody for Colon Carcinoma Treatment
IgA plays a major role in mucosal immunity, which is also used in cancer immunotherapy because of its excellent properties. Anti-carcinoembryonic antigen (CEA) IgA antibodies can lyse CEA positive tumor cells and induce tumor cell killing by ADCC and CDC. The cytotoxic effects and significant survival improvement of anti-CEA IgA antibodies indicated that these IgA antibodies exerted clinical anti-tumor effects. In addition, anti-epidermal growth factor receptor (EGFR) IgA mAbs are used to treat patients with colorectal cancer. It was reported that the IgA mAbs induced more effective tumor cell killing than cetuximab, a human IgG1 EGFR antibody used for the treatment of metastatic colorectal cancer, which is most likely because that EGFR IgA2 efficiently recruits polymorphonuclear granulocytes (PMNs), the most abundant effector cells population in the blood that expresses FcɑRI. Furthermore, serum IgA immune complex levels are elevated in colon cancer patients, indicating that the presence of IgA immune complexes might reflect a tumor-specific antibody response. IgA antibodies may also form dimers with an increased valency, which may augment their capacity to kill tumor cells. From this perspective, IgA represents an attractive isotype for immunotherapy of colorectal cancer.
IgM Antibody for Colon Carcinoma Treatment
IgM antibody usually functions as a pentamer form with a stronger ability to induce apoptosis of tumor cells. Studies have shown that spontaneously induced anti-CEA IgM antibodies are associated with improved survival in patients with colorectal cancer. Moreover, colon cancer, pancreatic cancer, and lung cancer patients can generate anti-tumor IgM monoclonal antibodies against these cancers. Several tumor-specific IgM antibodies have been isolated from patients with colon cancer. IgM antibodies induce cytotoxic effects on colon tumor cells may involve many mechanisms including (i) classical complement activation by binding to C1q; (ii) phagocytosis by indirect mannose-binding lectin complement activation; and (iii) inducer cell death in the domain-independent pathway by binding to corresponding cell surface receptors.
IgE Antibody for Colon Carcinoma Treatment
IgE antibodies can activate effector cells through surface IgE receptors and lyse tumor cells in ADCC. In addition, IgE antibodies have also been shown to inhibit the growth of CRC cells in mice and confer long-term anti-tumor immunity. Furthermore, mast cells may release tumor necrosis factor α (TNF-α) upon Fc-receptor binding of anti-tumor IgE antibodies and subsequently lyse tumor cells. Therefore, IgE antibodies play an important role in the treatment of colon cancer.
As a senior biological company, Creative Biolabs has won good reputations in antibody development service support in past years. We are confident in providing the best and professional service about non-IgG antibodies therapies for colon cancer. Moreover, other related and custom non-IgG antibodies service are also within our abilities.
If you are interested, please contact us without hesitation, we can customize our offering to meet your specific project needs.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
